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 Introduction
 Since their introduction about half a century ago, an-
tipsychotics constituted the mainstay of pharmacologic 
treatment of schizophrenia. For years, it has been stated 
in textbooks and guidelines that the onset of antipsychot-
ic action is delayed and that it takes 8 weeks or more be-
fore the onset of therapeutic benefits is produced  [1] . 
However, in the last years a growing body of evidence has 
shown that a substantial amount of improvement occurs 
within 2 weeks or less of initiating antipsychotic treat-
ment, with effects seen in some patients as early as 24 h 
 [1, 2] . Failure to respond within this time frame has been 
shown to strongly predict later non-response in several 
studies  [3–7] . These studies applied various symptom im-
provement thresholds to define early response, including 
the absolute lack of improvement (0% reduction of BPRS 
score), a 10% symptom reduction, as well as 20% symp-
tom improvement on the BPRS or PANSS. Also the time 
point at which early response was assessed in previous 
studies was different, but most of them focused on the 
response after 2 weeks of treatment. Despite such meth-
odological differences, overall these studies demonstrat-
ed that early non-response to antipsychotic treatment is 
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 Abstract
 Background and Aims: Time of onset of antipsychotic ac-
tion is still a debated matter. We aimed to replicate and 
 extend previous findings that early response can predict 
subsequent non-response.  Methods: 86 acutely psychotic 
patients treated with haloperidol were studied.  Results: A 
PANSS reduction  ^  16% at 1 week predicts non-response at 
3 weeks of treatment (specificity 92%, sensitivity 82%). Con-
versely, a PANSS reduction  6 23% at 1 week of treatment 
predicts response at 3 weeks, with a specificity of 84% and a 
sensitivity of 86%.  Conclusion: Our results confirm that an 
early response to antipsychotic treatment accurately pre-
dicts the treatment effectiveness and extends it to a predic-
tion performed as early as 1 week.
 Copyright © 2012 S. Karger AG, Basel
 Received: December 13, 2011
 Accepted after revision: March 1, 2012
 Published online: July 17, 2012 
 Alessandro Serretti, MD, PhD
 Institute of Psychiatry, University of Bologna
 Viale Carlo Pepoli 5, IT–40123 Bologna (Italy)
 Tel +39 051 658 4233
 E-Mail alessandro.serretti   @   unibo.it 
 © 2012 S. Karger AG, Basel
 0302–282X/12/0662–0100$38.00/0 
 Accessible online at:
 www.karger.com/nps 
 I.G., S.P., M.S., D.R. and A.S. contributed equally to this work. 
 Antipsychotic Early Response Neuropsychobiology 2012;66:100–105 101
a robust predictor of subsequent lack of response in pa-
tients with schizophrenia. These findings have important 
implications for the treatment of patients with schizo-
phrenia: they may allow to avoid ineffective treatments 
and the side effects related to them, to ensure an adequate 
trial in subjects who are likely to benefit, to early identify 
subjects who may benefit from a different antipsychotic 
agent and, therefore, to reduce the long-term clinical, 
functional, and economic harm associated with inade-
quate treatment  [8] . Taking into account the high clinical 
relevance that early prediction of response may represent, 
we aimed to replicate the previous finding that early re-
sponse can predict subsequent non-response at endpoint 
in a sample of acutely ill patients treated with haloperidol. 
We focused on the response after 1 week of treatment in 
order to verify if also at this point it may represent a ro-
bust predictor of the final outcome. More in details, the 
aims of the present study were: (1) to evaluate whether 
early response (defined as the percentage reduction of 
PANSS total score at 1 week of treatment, adjusted for the 
minimum score of the scale) can predict the outcome at 
the endpoint (defined according to the adjusted percent-
age reduction of PANSS total score at 3 weeks of treat-
ment), and (2) to identify the optimal early response 
threshold that best predicts subsequent resistance at 3 
weeks of treatment.
 Materials and Methods
 Patients
 Data for this study were drawn from a 4-week naturalistic 
study of haloperidol in psychotic patients [for details, see  9] . In 
brief, acutely psychotic inpatients for this study were enrolled 
when admitted at the Department of Psychiatry, Ludwig Maxi-
milians University of Munich, Germany. Inclusion criteria were: 
age from 18 to 60 and a diagnosis of schizophrenia confirmed by 
two psychiatrists by administration of the Structured Clinical 
Interview for DSM-III-R axis I disorders (SCID-I) interview. Ex-
clusion criteria were a known contraindication for treatment 
with haloperidol, tardive dyskinesia, severe neurological or med-
ical disorders, organic brain diseases, pregnancy and acute sui-
cidality. Furthermore, at baseline, patients were excluded if they 
received co-medication, such as   -blockers, antidepressants, bi-
periden or benzodiazepines with a possible influence on the an-
tipsychotic treatment and its side effect. Patients were treated 
with haloperidol without any dose limitation during the acute 
phase of the illness. After this phase, they were switched to a 
second-generation antipsychotic either if they developed motor 
side effects or for maintenance after the control of positive symp-
toms was reached. Only data deriving from the first phase of the 
study were used for the purposes of the present work. Patients 
were assessed for their socio-demographic and clinical variables 
at baseline, and symptoms severity was assessed using the PANSS 
scale at baseline and days 1, 7, 14, 21, and 28  [10] . Haloperidol-
induced side effects were assessed through the following tests: 
Extrapyramidal Symptom Rating Scale (ESRS)  [11] , Udvalg for 
Kliniske Undersøgelser side effects rating scale (UKU)  [12] , and 
the Barnes Akathisia Scale (BAS)  [13] . All the scales were admin-
istered by two senior psychiatrists; inter-rater evaluation gave re-
liable results (   1 0.80). The study was approved by the local eth-
ics committee and carried out in accordance to the ethical stan-
dards laid down in the 1964 Declaration of Helsinki. Written 
informed consent was obtained at the recruitment for each pa-
tient included.
 Statistical Analysis
 In order to examine the ability of early improvement to predict 
patients’ response status at endpoint, receiver-operating charac-
teristics (ROC) curves with area under the curve (AUC) values 
were calculated. The ROC curve is a graphical plot of sensitivity 
versus (1-specificity) and the AUC represents a measure of the 
overall discriminative power: a value of 0.5 for the AUC indicates 
no discriminative ability, while a value of 1.0 indicates a perfect 
power  [14] . The percentage PANSS reduction at 1 week was used 
as a predictor and it was calculated using the formula P% = [(P0–
P1)/P0]  ! 100, where P0 was PANSS score at baseline and P1 was 
PANSS score at 1 week of treatment  [15–17] . According to the sug-
gestions by Obermeier et al.  [15, 17] and Leucht et al.  [16] , PANSS 
scores were corrected by subtracting 30 points (the minimum val-
ue of PANSS scale) to every PANSS score before calculating per-
cent changes. Subsequent response was calculated at 3 weeks of 
treatment instead of 4 due to the high number of subjects exiting 
the study (56 patients) at the fourth week of the study and it was 
defined as follows: (1) poor response:  ! 26% reduction in adjusted 
PANSS score at 3 weeks of treatment  [18] and (2) good response: 
 1 51% reduction in adjusted PANSS score at 3 weeks of treatment 
 [18] .
 We also searched for the cut-off (early response threshold) 
that represents an optimum trade-off between sensibility and 
specificity by identifying the point of the curve with the maxi-
mum Youden index. The Youden index is an indicator for the 
balance between sensitivity and specificity and its formula is: 
Youden index = sensitivity (%) + specificity (%) – 1, the optimum 
value being +1  [19] . Data were analyzed with R software version 
2.12.1.
 Results
 A total of 101 subjects were enrolled in the study; 
among them, 15 dropped out before the third week of the 
study (all of them experienced intolerable side effects) 
and were therefore excluded from the analysis. The final 
sample was therefore constituted by 86 subjects. Clinical 
and demographic characteristics of the sample are re-
ported in  table  1 . The results of the ROC analysis are 
summarized in  table 2 . ROC curves are reported in  fig-
ure 1 (early response as a predictor of poor response at 3 
weeks) and  figure 2 (early response as a predictor of good 
response at 3 weeks). Early response (i.e. the percentage 
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PANSS reduction at 1 week of treatment) showed to be a 
good predictor of subsequent response at 3 weeks of treat-
ment: AUC was  1 0.9 both for poor improvement and for 
good improvement, indicating an excellent discrimina-
tive ability. The cut-off with the best trade-off between 
sensibility and specificity as assessed with the Youden in-
dex was 16% for patients showing a poor response. Thus, 
a PANSS reduction  ^  16% at 1 week predicts a less than 
26% PANSS reduction (‘poor response’) at 3 weeks of 
treatment, with good values of specificity (92%), sensitiv-
ity (82%), positive predictive value (85%) and negative 
predictive value (78%). The best threshold for the predic-
tion of a good response according to Youden index was 
23%, which means that a PANSS reduction  6 23% at 1 
week of treatment predicts a good response (i.e. a PANSS 
reduction  6 51%) at 3 weeks, with a specificity of 84%, a 
sensitivity of 86%, a positive predictive value of 75% and 
a negative predictive value of 88%. Overall these data sug-
gest that when a patient does not achieve a symptom re-
duction of at least 16% within the first week of treatment, 
it is likely that at 3 weeks of treatment it will display a re-
sistance to current treatment (i.e. a symptom reduction 
 ^  26%). Further, when a symptom reduction  6 23% is ob-
tained within the first week of treatment, it is possible to 
predict a good response (a symptom reduction  6 51%) at 
3 weeks of treatment.
 Discussion
 The present study was carried out to evaluate whether 
early response to antipsychotic drug treatment (i.e. per-
centage symptom reduction at 1 week of treatment, ad-
justed for the minimum score of PANSS scale) can pre-
dict subsequent response at endpoint, defined according 
to the adjusted PANSS total score percentage reduction at 
3 weeks of treatment. We also investigated the optimal 
early response threshold that best predicts subsequent re-
sistance at 3 weeks of treatment.
 Although for decades it has been stated in textbooks 
and guidelines that the onset of antipsychotic action is 
delayed, recent research has showed that it can occur rap-
 Table 1. C linical and demographic characteristics of the sample (mean 8 SD)
 Variable  Results 
 Age, years  35811.6 
 Sex  Male = 48 (56%), female = 38 (44%) 
 Age at onset, years  29.389.8 
 Disease duration, years  5.688.1 
 PANSS score at baseline  104818 
 Number of episodes  2.883.2 
 Number of hospitalizations  2.782.7 
 Previous antipsychotic medication  Yes = 69 (80.2%), no = 17 (19.7%) 
 Haloperidol dosage day 7, mg/day  11.3685.88 
 Haloperidol dosage day 21, mg/day  10.986.5 
 Diagnosis  Schizophrenia, paranoid type = 44 (51.1%) 
 Schizophrenia, undifferentiated type = 4 (4.6%) 
 Schizophrenia, catatonic type = 4 (4.6%) 
 Schizophrenia, disorganized type = 3 (3.4%) 
 Schizoaffective disorder = 17 (19.7%) 
 Brief psychotic disorder = 8 (9.3%) 
 Delusional disorder = 2 (2.3%) 
 Schizophreniform disorder = 4 (4.6%) 
 Table 2. P rediction of response at 3 weeks by percentage PANSS 
reduction at 1 week
Outcome AUC Thresh-
old, %1
Sensi-
tivity, %
Speci-
ficity, %
PPV
%2
NPV
%3
 Poor response  0.923  16  82  92  85  78 
 Good response  0.915  23  86  84  75  88 
1 Percentage PANSS reduction at 1 week with the best trade-off between 
sensitivity and specificity according to Youden index.
2 Positive predictive value.
3 Negative predictive value.
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idly within the first 2 weeks (‘early-onset hypothesis’)  [1] . 
The time course of antipsychotic response has important 
implications for medical management of acutely ill pa-
tients with schizophrenia and other psychotic disorders. 
Indeed, the early identification of patients who are likely 
to do not respond may minimize exposure to ineffective 
treatment and related side effects and thus may reduce 
healthcare costs and improve overall outcome in psy-
chotic patients  [8] . In the last years, several studies have 
suggested that early response can predict subsequent re-
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 Fig. 1. Early response as a predictor of poor response at 3 weeks. 
 Fig. 2. Early response as a predictor of good response at 3 weeks 
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sponse and that patients who do not respond to treatment 
in the first weeks may probably benefit from a change of 
treatment  [4–7, 20–23] . We therefore attempted to repli-
cate these findings in a naturalistic sample of 86 acute 
psychotic patients treated with haloperidol. Our study 
confirmed that it is possible to predict antipsychotic re-
sponse since the first week of treatment: the AUC values 
were very high both for poor responders and for good re-
sponders, while the early response threshold with the best 
trade-off between sensitivity and specificity was 16 and 
23% respectively, with very high values of sensitivities, 
specificities, positive and negative predictive values. As 
from a clinical point of view it is more relevant to iden-
tify those patients that will be resistant to the current 
treatment early, the 16% reduction threshold may be 
more important in daily clinical practice. Our results 
suggest that this threshold can be used to predict the sub-
sequent patient’s response; a failure to achieve a 16% 
symptom reduction in the first week of treatment indi-
cates that the patient is likely to be resistant at 3 weeks of 
treatment, and may therefore benefit from a change of 
treatment. Indeed, our definition of response, derived 
from the adjusted PANSS total score percentage reduc-
tion at 3 weeks of treatment, is related to longer term mea-
sures of outcome according to some recent evidence. Par-
ticularly, results from a large meta-analysis of literature 
including 1708 patients revealed that percentage reduc-
tion in the first weeks of treatment was significantly high-
er than the additional change in the BPRS during the rest 
of the year: 68% of the total BPRS effect was already 
achieved after only 4 weeks of treatment  [24] .
 Previous research used different symptom improve-
ment thresholds to define early response/non-response, 
including an absolute lack of symptom improvement 
(0%)  [6, 20] , a  6 10% symptom improvement  [7] , to 20% 
symptom improvement from baseline on the BPRS or 
PANSS  [4, 5, 21–23] . The time point at which early re-
sponse/non-response was assessed in previous studies 
also varied, but most of them focused on the second week 
of treatment  [4, 5, 20, 22, 23] . Therefore, our results allow 
to confirm and to extend previous findings to the first 
week of treatment. Our study has several limitations that 
must be taken into account in the interpretation and gen-
eralization of the results. First, the main limitations were 
the relatively small sample size and the high number of 
subjects exiting the study that did not allow us to evaluate 
the predictive power of early response on subsequent re-
sponse at 4 weeks of treatment. Second, our patients were 
from markedly to severely ill (mean PANSS score at base-
line 104  8 18)  [18] . Thus, if on the one hand our results 
clearly demonstrate the early onset of antipsychotic re-
sponse and its usefulness in daily clinical practice, on the 
other hand the question of whether patients with differ-
ent severity would show a similar pattern of response still 
remains unsolved. Third, our sample included only pa-
tients treated with haloperidol, a typical antipsychotic 
that is often used in the acute phase of psychosis for its 
fast action  [2] . Therefore the extension of our results to 
other agents is not warranted. Nonetheless, according to 
the meta-analysis of Agid et al.  [1] , the observed pattern 
of response is likely to be similar with other antipsychot-
ic treatment. Furthermore, our patients were treated with 
a haloperidol monotherapy, thus we can exclude unspe-
cific effects due to symptomatic therapies, like benzodi-
azepines, in our sample. Finally, 80% of patients were 
treated with other antipsychotics in the past, thus the ob-
served pattern of response may be altered by previous an-
tipsychotic treatments. Although we cannot exclude this 
possibility, it seems to be unlikely, because several previ-
ous studies on this issue included drug-free or drug-naive 
patients and uniformly observed a rapid response  [25–
31] . Further, it should be considered that in our sample 
the 20% of patients were drug-free at the recruitment.
 It should be underlined that our sample included pa-
tients treated with variable doses of haloperidol. There-
fore, considering that increasing the haloperidol dose up 
to about 9 mg/day within the first 2 weeks of treatment 
can lead to a clinical improvement while further increas-
ing do not result in further amelioration  [9] , we repeated 
the analysis after exclusion of patients who received an 
increasing dose within this dose threshold of haloperidol 
during the first 2 weeks of treatment. Probably due to the 
low number of those patients (only 3), our results did not 
change (data not shown).
 Conclusions
 Our results confirm that early non-response to anti-
psychotic treatment accurately predicts subsequent non-
response to continued treatment with the same antipsy-
chotic agent. A threshold of 16% reduction can be used in 
clinical practice to identify those patients who are un-
likely to respond to antipsychotic therapy. As previously 
reported, identifying early non-responders is an impor-
tant step in the management of patient with schizophre-
nia and other psychotic disorders since it can help to min-
imize exposure to suboptimal or ineffective treatment 
strategies, reduce healthcare costs and improve overall 
outcome in psychotic patients  [8] . 
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